Innate Pharma (IPHA)

P/S ratio at the end of 2022: 5.63

According to Innate Pharma 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 2.40. At the end of 2022 the company had a P/S ratio of 5.63.

P/S ratio history for Innate Pharma from 2006 to 2022

PS ratio at the end of each year

Year	P/S ratio	Change
2022	5.63	-80.74%
2021	29.2	499.83%
2020	4.87	-28.87%
2019	6.85	14.91%
2018	5.96	-28.38%
2017	8.32	-40.95%
2016	14.1	-65.38%
2015	40.7	-91.17%
2014	461	2436%
2013	18.2	129.2%
2012	7.93	49.23%
2011	5.31	-47.74%
2010	10.2	-13.41%
2009	11.7	326.27%
2008	2.76	-37.43%
2007	4.40	-65.51%
2006	12.8

What is the market capitalization of a company?

The market capitalization sometimes referred as Marketcap, is the value of a publicly listed company.
In most cases it can be easily calculated by multiplying the share price with the amount of outstanding shares.

DISCLAIMER

CompaniesMarketCap is not associated in any way with CoinMarketCap.com
Stock prices are delayed, the delay can range from a few minutes to several hours.
Company logos are from the CompaniesLogo.com logo database and belong to their respective copyright holders. Companies Marketcap displays them for editorial purposes only.

Contact

For inquiries or if you want to report a problem write to hello@8marketcap.com

Links

- Privacy policy

- Terms and conditions

P/S ratio for Innate Pharma (IPHA)